InnovAge Holding (INNV) concentration risks

InnovAge Holding's revenue is almost entirely tied to a single program: the PACE program accounted for 99.8% of revenue in each of the years ended June 30, 2025 and 2024, a high-scale structural concentration that defines the business model itself rather than reliance on any external counterparty. Layered on top of that, a majority of revenue was derived from a limited number of government payors, including Medicare and Medicaid, a moderate-scale exposure the filing characterizes as mixed in nature. These two exposures are closely linked but distinct in what could move the thesis. The PACE concentration is essentially total — there is no meaningful revenue diversification outside this one program, so any regulatory or reimbursement change affecting PACE would flow through almost the entire business. The government-payor concentration sits inside that same structure, reflecting how PACE itself is funded, and its mixed character suggests both funding stability (government payors are generally reliable, recurring counterparties) and policy-driven risk (reimbursement rates and program funding are set externally). Together, the two exposures describe a company whose fortunes are almost entirely determined by the durability and funding of a single government-linked care program.

For the engine’s reasoning on INNV’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.